Prospective trials compare early antidepressant effects in treatment-resistant depression, suggesting further validation is needed.
aTMS showed a stronger early antidepressant effect, but its advantage over esketamine progressively diminished and was no longer evident at six months. Prospective, well-powered comparative trials are required to validate these findings.
No takes yet. Share an insight, caveat, or question.
Prato et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: